ArticleJournal of immunology (Baltimore, Md. : 1950)2016
NKAP Regulates Invariant NKT Cell Proliferation and Differentiation into ROR-γt-Expressing NKT17 Cells.
Article in Journal of immunology (Baltimore, Md. : 1950), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 33 citations in OpenAlex.
- Deleterious NKAP Mutations Are Associated with Musculoskeletal Abnormalities in Hemizygous Males and Skewed X Chromosome Inactivation in Heterozygous Females.International journal of molecular sciences · 2026Article
- NKAP overexpression promotes gastric cancer immune escape by inducing IL-10 secretion from mature dendritic cells during anti-PD-L1 therapy.Journal of gastrointestinal oncology · 2025Article
- NKT cells-a generalist in disease treatment and a new key to unlock immunotherapy.Immunotherapy · 2025Review
- Impaired dNKAP function drives genome instability and tumorigenic growth in Drosophila epithelia.Journal of molecular cell biology · 2024Article
- From phenotype to mechanism: Prenatal spectrum of NKAP mutation-related disorder and its pathogenesis inducing congenital heart disease.Journal of cellular and molecular medicine · 2024Article
- Markers and makers of NKT17 cells.Experimental & molecular medicine · 2023Review
- CD138 expression is a molecular signature but not a developmental requirement for RORγt+ NKT17 cells.JCI insight · 2021Article
- Natural Killer T Lymphocytes Integrate Innate Sensory Information and Relay Context to Effector Immune Responses.Critical reviews in immunology · 2021Review
- Recent Update of HDAC Inhibitors in Lymphoma.Frontiers in cell and developmental biology · 2020Review
- NKAP functions as an oncogene in Ewing sarcoma cells partly through the AKT signaling pathway.Experimental and therapeutic medicine · 2019Article
- Synthetic Essentiality of Metabolic Regulator PDHK1 in PTEN-Deficient Cells and Cancers.Cell reports · 2019Article
- Coexpression of YY1 Is Required to Elaborate the Effector Functions Controlled by PLZF in NKT Cells.Journal of immunology (Baltimore, Md. : 1950) · 2019Article
- NKAP alters tumor immune microenvironment and promotes glioma growth via Notch1 signaling.Journal of experimental & clinical cancer research : CR · 2019Article
- NKAP Must Associate with HDAC3 to Regulate Hematopoietic Stem Cell Maintenance and Survival.Journal of immunology (Baltimore, Md. : 1950) · 2019Article
- NKAP Regulates Senescence and Cell Death Pathways in Hematopoietic Progenitors.Frontiers in cell and developmental biology · 2019Article
- The ins and outs of type I iNKT cell development.Molecular immunology · 2019Review
- Differential Control ofFrontiers in immunology · 2019Article
- NKAP functions as an oncogene and its expression is induced by CoClCancer management and research · 2018Article
- The differentiation of ROR-γt expressing iNKT17 cells is orchestrated by Runx1.Scientific reports · 2017Article
- Histone deacetylase 3 is required for iNKT cell development.Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Invariant NKT (iNKT) cells are a unique lineage with characteristics of both adaptive and innate lymphocytes, and they recognize glycolipids presented by an MHC class I-like CD1d molecule. During thymic development, iNKT cells also differentiate into NKT1, NKT2, and NKT17 functional subsets that preferentially produce cytokines IFN-γ, IL-4, and IL-17, respectively, upon activation. Newly selected iNKT cells undergo a burst of proliferation, which is defective in mice with a specific deletion of NKAP in the iNKT cell lineage, leading to severe reductions in thymic and peripheral iNKT cell numbers. The decreased cell number is not due to defective homeostasis or increased apoptosis, and it is not rescued by Bcl-xL overexpression. NKAP is also required for differentiation into NKT17 cells, but NKT1 and NKT2 cell development and function are unaffected. This failure in NKT17 development is rescued by transgenic expression of promyelocytic leukemia zinc finger; however, the promyelocytic leukemia zinc finger transgene does not restore iNKT cell numbers or the block in positive selection into the iNKT cell lineage in CD4-cre NKAP conditional knockout mice. Therefore, NKAP regulates multiple steps in iNKT cell development and differentiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.